Valuation: Medico Intercontinental Limited

Market Cap 248M 2.63M 2.39M 2.21M 1.99M 3.75M 3.89M 26.52M 10.51M 133M 9.88M 9.67M 421M P/E 2025
7.01x
P/E 2026 -7.97x
Enterprise Value 860M 9.12M 8.26M 7.64M 6.9M 13M 13.46M 91.83M 36.41M 459M 34.23M 33.5M 1.46B EV / Sales 2025
0.52x
EV / Sales 2026 1.02x
Free-Float
38.75%
Yield 2025 *
-
Yield 2026 -
11-06 Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026 CI
08-14 Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
05-22 Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-14 Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
14/08/25 Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
14/07/25 Medico Intercontinental Limited Approves the Appointment of Puneeta Sharma as Company Secretary and Compliance Officer, Effective from 14 July, 2025 CI
31/05/25 Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2025 CI
22/04/25 Medico Intercontinental Limited Announces Resignation of Puneeta Sharma as Company Secretary & Compliance Officer, Effective 22 April, 2025 CI
14/11/24 Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 CI
13/08/24 Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2024 CI
25/05/24 Medico Intercontinental Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
25/05/24 Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
25/04/24 Medico Intercontinental Limited Announces Resignation of Nikul Dipakbhai Shah as Independent Director CI
1 day-0.44%
1 week-2.55%
Current month+0.57%
1 month-4.46%
3 months-11.98%
6 months+7.30%
Current year-37.92%
1 week 24.1
Extreme 24.1
29
1 month 21
Extreme 21
29
Current year 20.61
Extreme 20.61
42.9
1 year 20.61
Extreme 20.61
43
3 years 20.61
Extreme 20.61
122
5 years 20.61
Extreme 20.61
122
10 years 8
Extreme 8
132.1
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 12/08/2019
Compliance Officer - 01/06/2019
Director TitleAgeSince
Chairman - 08/04/2019
Director/Board Member 53 23/03/2019
Director/Board Member - 14/11/2022
Change 5-day change 1-year change 3-year change Capi.($)
-0.44%-2.55%-26.86%-71.29% 2.63M
+1.26%+6.61%+40.79%+136.32% 1,286B
+0.79%+3.45%+45.84%+93.52% 688B
+0.20%+1.28%+26.97%+113.70% 521B
-0.44%+3.69%+41.45%+68.91% 386B
+0.55%+0.70%+59.02%+44.62% 364B
-0.12%+0.74%+28.39%+58.54% 302B
+0.37%+0.37%+3.33%+37.27% 287B
-0.30%+1.14%+38.29%+72.46% 252B
+0.08%+0.71%+34.44%+124.95% 208B
Average +0.20%+1.61%+29.17%+67.90% 429B
Weighted average by Cap. +0.54%+3.26%+37.70%+96.50%

Financials

2025 2026
Net sales 963M 10.21M 9.25M 8.56M 7.72M 14.55M 15.06M 103M 40.77M 514M 38.32M 37.51M 1.63B 846M 8.97M 8.13M 7.52M 6.79M 12.79M 13.24M 90.35M 35.83M 452M 33.67M 32.96M 1.43B
Net income 50.57M 536K 486K 450K 406K 764K 791K 5.4M 2.14M 27.01M 2.01M 1.97M 85.75M -32.01M -339K -308K -285K -257K -484K -501K -3.42M -1.36M -17.1M -1.27M -1.25M -54.27M
Net Debt 142M 1.51M 1.37M 1.27M 1.14M 2.15M 2.23M 15.2M 6.03M 76.03M 5.67M 5.54M 241M 612M 6.49M 5.88M 5.44M 4.91M 9.24M 9.57M 65.31M 25.9M 327M 24.34M 23.83M 1.04B
Projected Income Statement - Annual - Medico Intercontinental Limited
Logo Medico Intercontinental Limited
Medico Intercontinental Ltd is engaged in the business of trading pharmaceutical products. It provides a platform for all research-based biopharmaceutical companies. Its product categories include Gastro, Uro, Nutrition, Cosmetology, Health devices, Hospital, and other areas. Its products include ACIFACT-BLI, ACIFACT-P, ACIFACT-SP (ALU-ALU), ALBECTIN, ALFACARE-D3, ARSUFACT Combokit, BALOFACT, CYCLOFACT 400, UDIFACT 150, XOFACT-4, ZIFT SL-250, ZYMIX, ARGIFACT, CLIANCIACT POWDER, RELIEVE CZ, VOLIREX SPRAY, RACIMAX SACHET, PERMACT, OROFACT, KTZ, FEMYACT, LIVOFACT, ZYMIX SY, ULTRATONE SY, ALBECTIN SUS, BECOFACT DROPS, MEFACT P SUS, ONCARE SOLUTION, OFCARE-FORTE SUS, PRODOM CV SY, RELIBEN SUSP, ZIFT SUSP-200, MGCIPACT EYE DROP, OROFACT-PASTE (lamy), OROFACT MOUTH ULCER GEL, CAMBOGIA, LUBRIACT, HIZEN, and CALAMED LOTION. Its subsidiaries include Evagrace Pharma Private Limited, Ritz Formulations Private Limited, Sungrace Pharma Private Limited, and Azillian Healthcare Private Limited.
Employees
41
Date Price Change Volume
13/11/26 ₹24.83 -0.44% 245
12/11/26 ₹24.94 -8.34% 3,339
11/11/26 ₹27.21 +5.67% 1,320
09/11/26 ₹25.75 -0.92% 173
08/11/26 ₹25.99 +2.00% 128
  1. Stock Market
  2. Stocks
  3. 539938 Stock